AstraZeneca Plc. presented Phase III results for Vandetanib drug, indicated to treat advanced medullary thyroid cancer (MTC), the company showed results at the American Society of Clinical Oncology Congress (ASCO) that takes place in Chicago.

Peregrine Pharmaceuticals Inc. announced that a Phase II trial showed that 74 percent of Bavituximab tested in women with breast cancer, in combination with chemotherapy drugs paclitaxel and carboplatin, responded to treatment.

CytRx Corporation announced initiation of Phase II study for Bafetinib (previously known as INNO 406) among patients with B-cell chronic lymphocytic leukemia (B-CLL).

Merck & Co. Jointly with Cardiome Pharma Corp. Presented Phase III results on intravenous experimental drug for atrial fibrillation, Brinavess (Vernakalant). The product showed superiority compared to Amiodarone in converting patients heart rate from atrial fibrillation to normal rate.

AstraZeneca Plc, said that experimental drug Olaparib, showed positive results in Phase I clinical trial to treat ovarian cancer. The drug is a poly ADP-ribose polymerase (PARP) inhibitor, an enzyme that repairs DNA damage.

Avanir Pharmaceuticals Inc. experimental drug, Zenvia (Quinidine+ Dextromethorphan) showed in a clinical study presented at the American Academy of Neurology taken place in Toronto (Canada) to reduce episodes of involuntary laughing and crying caused in patients in multiple sclerosis, amyotrophic lateral sclerosis and other brain disorders. The brain disorder is called pseudobulbar affect.

French Sanofi-Aventis SA announce license agreement with privately held U.S. drug maker CureDM Inc. for world´s rights of Pancreate (Proisletide Acetate) used to restore the body´s capacity to produce insulin and other pancreatic hormones in type 1 and type 2 diabetes patients. The deal could reach $335 M.

U.S. GenVec Inc. announced their decision to stop Phase III study of experimental gene therapy drug TNFerade to treat patients with pancreatic cancer, because interim results of pivotal study (known as PACT) showed it was unlikely to prove effective.

British biotechnology Company Antisoma Plc. announced that their experimental drug ASA 404 did not meet late stage-stage trial objective, as it did not showed any survival benefit in patients previously treated with non-small cell lung cancer drugs.

Biotechnology NPS Pharmaceuticals Inc., presented positive results on three Phase III clinical trials of experimental drug to treat short bowel syndrome, Gattex (Teduglutide)

Biotechnology controlled by Sanofi-Aventis SA, BiPar Sciences, presented at the American Society of Clinical Oncology Congress data for Phase II of its triple negative drug BSI 201 drug to treat breast cancer.

Catalyst Pharmaceutical Partner Inc. experimental drug to treat cocaine addiction did not meet Phase II clinical objectives. The drug known as CPP 109 (Vigabatrin) is also under test for methamphetamines addiction.

British Biotechnology Neuropharm Group Plc. said the expect to sign an agreement with a big drug maker in the following months to development and commercialization of NPL 2008.

Cadence Pharmaceuticals Inc said its painkiller, Acetavance, met the primary goal of a last-stage trial. Further Details

U.S. biopharmaceutical company XenoPort Inc said its treatment to reduce symptoms of acid reflux, XP19986, failed to meet the main goal in a mid-stage study. However, as a monotherapy, the experimental drug was effective in reducing heartburn in a subgroup of patients.

French biotechnology company NicOx SA said that Naproxcinod, showed positive results in advanced clinical testing. Naproxcinod is derived drug from the standard painkiller naproxen, without typical naproxen side effects such as hypertension.